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A B S T R A C T
Introduction: Asthma in obese subjects is poorly understood. According to GINA guidelines, pulmonologists
increase ICS in case of poor asthma control but lung volume restriction may also worsen respiratory symptoms in
obese asthmatics leading to overtreatment in this subpopulation.
Methods: We conducted a retrospective study on 1217 asthmatics recruited from University Hospital of Liege. 92
patients with a BMI ≥30 came at least two times at the asthma clinic (mean interval: 335 days). In this obese
population, we identified predictors of good (decrease in ACQ ≥0.5) versus poor response (rise in ACQ ≥0.5) to
ICS step-up therapy.
Results: Obese asthmatics had a poorer asthma control and quality of life as compared to non-obese and ex-
hibited reduced FVC, higher levels of blood leucocytes and markers of systemic inflammation. The proportion of
asthma inflammatory phenotypes was similar to that observed in a general population of asthmatics. Among
uncontrolled obese asthmatics receiving ICS step-up therapy, 53% improved their asthma control while 31% had
a worsening of their asthma. Uncontrolled obese asthmatics showing a good response to increase in ICS had
higher ACQ, lower CRP levels, higher sputum eosinophil counts and higher FeNO levels at visit 1. Uncontrolled
obese asthmatics that worsened after increasing the dose of ICS had lower FVC, lower sputum eosinophil counts
and higher sputum neutrophil counts.
Conclusion: We observed poorer asthma control in obese asthmatics despite similar bronchial inflammation.
Managing obese asthmatics according to ACQ alone seems to underestimate asthma control and the contribution
of restriction to dyspnea. Increasing the dose of ICS in the absence of sputum eosinophilic inflammation or in the
presence of restriction or bronchial neutrophilia led to poorer asthma control. In those patients, management of
obesity should be the first choice.
1. Introduction
Asthma in obese subjects is poorly understood. Asthma and obesity
are both common diseases in developed countries. More than 600
million people are obese worldwide. According to the data from our
asthma clinic, 20% of our asthmatics are obese and this rate increases
up to 25% in severe asthmatics included in the Belgian Severe Asthma
Registry [1]. The majority of studies evaluating the link between obe-
sity and the prevalence and incidence of asthma in adults or exploring
the relationship between obesity and asthma severity concluded that
obesity was associated with a significant increase in the annual risk of a
new diagnosis of asthma [2–4]. The association of obesity with severe
asthma remains controversial. It has been suggested that obesity was a
consequence of asthma treatment but it is now clear that obesity often
precedes asthma [5]. Mechanical [6], inflammatory and genetic factors
[7] contribute to the development of asthma in obese patients [8].
The aim of asthma management is to obtain asthma control and to
reduce the risk of exacerbation. The GINA guidelines [9] recommend to
step-up or step-down the ICS dose according to asthma symptoms
questionnaires. However, obese patients do not respond as well as
normal-weight individuals to inhaled corticosteroids or inhaled corti-
costeroid/long-acting bronchodilator combination medications [10,11]
Obesity indeed causes physiologic impairment in lung function due to
the mechanical effect of central body fat distribution [12] and symp-
toms related to lung volume restriction will not improve with a step-up
of asthma therapy. This could lead to obese asthma overtreatment. In
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the area of personalized medicine, the obese-asthma phenotype remains
controversial [13–16], some of the clusters analysis suggesting that this
obese asthma phenotype is not a uniform group and identifying two
major subgroups according to TH2 inflammation and the age of onset.
The aim of this study was to describe the characteristics of obese as
compared to normal-weight asthmatics and to identify predictors of
poor or good responders to ICS step-up therapy in this particular
asthmatic population.
2. Material and methods
2.1. Subject characteristics
We conducted a retrospective study on a series of 1217 patients with
asthma recruited from the University Asthma Clinic of Liege between
October 2005 and June 2017. The patients came from routine practice
to University Hospital and were recruited by two clinicians involved in
asthma. Entry criteria were any patients with asthma aged 18yrs or
more who accepted to undergo detailed investigation at the Asthma
Clinic. The visits were not parts of an asthma trial. All the patients that
had a successful sputum induction were included in the study. Their
demographic and functional characteristics are summarised in Tables 1
and 2.
Asthma was diagnosed based on the presence of chronic respiratory
symptoms such as cough, breathlessness or dyspnoea together with the
demonstration of airflow variability. The latter was defined by airway
hyper-responsiveness shown by one or more of the following: increase
in Forced Expiratory Volume in 1 s (FEV1) of> 12% and 200 ml fol-
lowing inhalation of 400 µg salbutamol (VENTOLIN™, GSK Belgium) or
inhaled concentration of methacholine (Methapharm inc., Brandford,
Ontario, Canada) provoking a 20% fall in FEV1 of< 16 mg/ml.
Methacholine challenge was performed according to a standardised
methodology as previously described [17]. Subjects were characterised
as atopic if they had at least one positive specific IgE (> 0.35kU/l;
Phadia) for at least one common aeroallergen (cat, dog, house dust
mites, grass pollen, tree pollen and a mixture of moulds). Patients with
a smoking history of more than 20 pack-years were excluded. Subjects
with BMI under 30 were defined as non-obese and subjects with BMI
over 30 as obese asthmatics.
2.2. Study design
Patients underwent FeNO measurement at a flow rate of 50 ml/s
according to the ERS/ATS recommendations (NIOX, Aerocrine,
Sweden). FeNO was first measured and followed by spirometry with
bronchodilation, sputum induction and blood sampling. All tests were
performed on the same day.
Quality of life was assessed using the self-administered Asthma
Quality of Life Questionnaire (AQLQ [18]) and asthma control by the
Juniper Asthma Control Questionnaire (ACQ [19]). Sputum was in-
duced and processed as previously reported [20]. Cell count were es-
timated on samples centrifuged (Cytospin) and stained with Diff Quick
after counting 500 cells (Dade, Brussels, Belgium).
2.3. Statistical analyses
The results were expressed as means ± standard deviation (SD) for
continuous variables or as medians and interquartile ranges (IQR) for
skewed distributions. For categorical variables, the number of ob-
servations and percentages were given in each category. Comparisons
between different subgroups were performed with ANOVA test or a
Kruskal-Wallis test. The Spearman correlation coefficient was used to
measure the association between clinical parameters. Univariate linear
regression models were used to assess the relationship between ACQ,
AQLQ and BMI with a set of covariates. Some parameters were log-
transformed to normalize their distribution. ICS was divided in three
groups according to tertiles (< 400, ≥400-1000, ≥1000). A multi-
variate analysis with stepwise selection was done including all in-
dependent variables. The results were considered to be significant at the
5% critical level (p < 0.05). Calculations were done using SAS Version
9.1 (SAS Institute, Cary, North Carolina, USA).
Table 1
Demographic and clinical characteristics of asthmatics classified according to BMI.
Overall BMI < 30 BMI 30–35 BMI ≥ 35
N 1217 969 (80%) 177 (14%) 71 (6%)
Sex (F) 717 (59%) 565 (58%) 103 (58%) 49 (69%)
Age, years 49 (35–60) **** 47 (33–60) 54 (43–64) †††† 50 (37–62)
Smoking history (S/ES/NS), % 21/26/53 22/26/52 19/31/50 17/23/60
Packs-years 0 (0–10) 0 (0–8) 0 (0–17) 0 (0–7)
Atopy (Y) 706 (58%) 610 (63%) 97 (55%) 36 (51%)
Exacerbation (n/yr) 0.66 0.68 0.48 0.67
ICS 766 (63%) 594 (61%) 114 (64%) 55 (77%) ∞
Beclomethasone equivalents 400 (0–1000) ** 400 (0–1000) 800 (0–1000) 800 (200–2000) ∞∞
OCS 87 (7%) 65 (7%) 14 (8%) 8 (11%)
LABA 711 (58%) 541 (56%) 116 (66%) † 54 (76%) ∞∞
LTRA 292 (24%) 222 (23%) 44 (25%) 26 (37%) ∞
Anticholinergics 352 (29%) 267 (28%) 57 (32%) 28 (39%)
FEV1% 84 ± 21 84 ± 21 83 ± 22 80 ± 21
FVC% 95 ± 18 ** 96 ± 18 92 ± 21 89 ± 19 ∞∞
FEV1/FVC 73 ± 11 ** 73 ± 11 75 ± 11 76 ± 10∞
ACQ 2,01 ± 1,23 **** 1,93 ± 1,22 2,28 ± 1,21 †† 2,51 ± 1,21 ∞∞∞
ACT 15 ± 5 **** 15 ± 5 14 ± 5 † 12 ± 5 ∞∞∞
AQLQ 4,52 ± 1,36 **** 4,61 ± 1,34 4,25 ± 1,31 †† 3,84 ± 1,48 ∞∞∞∞
Age of onset 30 (11–50) 31 (12–49) 32 (12–84) 28 (10–51)
Early/late onset (< 12/>40 yr) 258/391 204/310 40/58 14/23
† compares BMI 30–35 to BMI < 30 group; ∞ compares BMI ≥ 35 to BMI < 30 groups; x compares BMI ≥ 35 to BMI 30–35 groups. */†/∞/ x : p < 0,05. **/††/
∞∞/ x x:p < 0,01. ***/†††/∞∞∞/ x x x: p < 0,001. ****/††††/∞∞∞∞/ x x x x: P < 0,0001.
BMI: body mass index. F: female. M: male. S: current smoker. ES: ex-smoker. NS: non-smoker. Y: yes. N/yr: number per year. ICS: inhaled corticosteroids. OCS: oral
corticosteroids. LABA: Long acting Beta 2 Agonists. LTRA: leukotriens receptor antagonists. FEV1: forced expiratory volume in one second. FVC: forced vital capacity.
ACQ: asthma control questionnaire. ACT: asthma control test. AQLQ: asthma quality of life questionnaire.




Complete assessment was obtained in 1217 subjects with physician-
diagnosed asthma. 20% of our general asthmatic population was obese
and 6% had a BMI ≥35. Female was the predominant gender and mean
age of our asthmatics was 49 years old with obese patients tending to be
older (Table 1). 21% were current smokers while 26% were ex-smokers.
Atopy did not differ according to BMI. Obese asthmatics received
higher doses of ICS and more frequently LABA and anti-leukotrienes
than non-obese. Overweight patients had poorer asthma control and
quality of life. 72% of our obese asthmatic population had uncontrolled
asthma. When looking more in depth at the ACQ questionnaire, it ap-
peared that obese patients had significantly more morning symptoms,
activity limitation, breathlessness and short-acting bronchodilator use
than non-obese (p < 0.05). They did not report more frequent noc-
turnal awakening or wheezing. Asthmatics with a BMI ≥30 had similar
FEV1 values but reduced FVC (Table 1). Early onset of asthma was
observed in one fifth of asthmatics while one third of the cohort had
onset of disease after the age of 40 years old and this was similar within
the different BMI subgroups.
Absolute value of blood leucocytes, including neutrophils, lym-
phocytes and monocytes were correlated with BMI with obese patients
showing the highest levels (Table 2). CRP and Fibrinogen levels also
increased with BMI. Successful sputum was obtained in 83% of the
asthmatic population. The proportion of airway inflammatory pheno-
types was similar in different weight subgroups (Fig. 1) but we found a
significant increase in absolute sputum neutrophil counts in obese pa-
tients. Obese did not exhibit higher rate of exacerbations.
3.2. Independent factors of poor asthma control and quality of life
We conducted a multiple regression analysis in the general popu-
lation of asthmatics to highlight independent predictors of asthma
control (Table 3). Higher BMI, tobacco smoking, sputum eosinophil
counts and high ICS dose were predictors of poorer asthma control
while higher FEV1 values were associated with better asthma control
(r2 = 0.40, p < 0.0001). As for quality of life, multiple logistic re-
gression analysis showed that male gender and higher FVC were in-
dependent predictors of better asthma quality of life while higher BMI
and high doses ICS were associated with poorer AQLQ (r2:0.23,
p < 0.0001).
3.3. Effect of ICS in obese asthmatics
Among the 146 uncontrolled asthmatics with normal weight that
were prescribed an ICS step-up therapy, 88 patients (60%) had an im-
provement of their asthma control at the following visit (decrease in
ACQ ≥0.5) while 33 patients (23%) had a worsening of their asthma
(increase ≥0.5 in ACQ score, Table 4). In the obese asthma population
where ICS step-up therapy was prescribed due to poor asthma control
(n = 57), 29 asthmatics (53%) improved their asthma control while 17
patients (31%) had a worsening of their asthma symptoms (Table 4).
The rate of responders did not significantly differ between obese and
normal-weight asthmatics (p > 0.05).
Table 2
Inflammatory characteristics of asthmatics classified according to BMI.
Overall BMI < 30 BMI 30–35 BMI ≥ 35
Blood leucocytes, 106/mm3 7,5 (6,2–9,1) *** 7,3 (6,1–8,9) 7,8 (6,7–9,4) † 8,2 (6,8–9,7)∞
Blood neutrophils, 103/mm3 4059 (3156–5392) ** 3970 (3061–5325) 4237 (3465–5607) 4482 (3685–5824)
Blood lymphocytes, 103/mm3 2328 (1869–2848) **** 2270 (1850–2771) 2558 (2035–3165) ††† 2528 (2002–3212)∞
Blood eosinophils, 103/mm3 190 (110–333) 191 (110–335) 181 (109–320) 184 (109–350)
Blood monocytes, 103/mm3 511 (397–668) ** 500 (388–657) 514 (424–672) 563 (465–725)∞
Blood basophils, 103/mm3 36 (24–53) 36 (23–53) 37 (27–57) 36 (23–54)
Blood neutrophils, % 56 (49–62) 56 (49–62) 56 (50–62) 57 (48–64)
Blood lymphocytes, % 32 (26–38) 32 (26–38) 33 (27–39) 31 (24–39)
Blood eosinophils, % 2,6 (1,5–4,3) 2,7 (1,5–4,5) 2,4 (1,6–4) 2,6 (1–4)
Blood monocytes, % 6,9 (5,4–8,5) 6,9 (5,4–8,6) 6,7 (5,4–8,4) 7,2 (5,7–8,8)
Blood basophils, % 0,5 (0,3–0,7) 0,5 (0,3–0,7) 0,5 (0,3–0,7) 0,4 (0,3–0,6)
CRP, mg/L 2,4 (1–6) **** 2 (0,9–6) 3,3 (2–6) †††† 4,4 (2.1–9,4)∞∞∞
Fibrinogen, g/L 3,2 (2,8–3,7) **** 3,2 (2,7–3,6) 3,5 (2,9–3,9) †† 3,7 (3,2–4,2)∞∞∞∞
IgE, kU/L 120 (39–335) 123 (40–349) 118 (41–302) 84 (34–269)
Total cell count (106/g) 1042 (311–3027) 1150 (241–3658) 1025 (188–2925) 1231 (481–3606)
IS eosinophils, 103/mm3 21 (0,5–173) 21 (0–176) 20 (1,9–138) 25 (0,5–192)
IS neutrophils, 103/mm3 474 (160–1556) 460 (156–1482) 548 (195–1849) 714 (198–2295)∞
IS lymphocytes, 103/mm3 14,6 (3,1–45,4) 13,8 (2,9–43,9) 16,4 (3–46,8) 19,7 (7,7–57,7)
IS macrophages, 103/mm3 262 (111–640) 258 (106–643) 257 (112–604) 345 (159–802)
IS eosinophils, % 1,8 (0,2–10,8) 1,8 (0,2–11) 1,6 (0,3–9,4) 1,8 (0,2–10,8)
IS neutrophils, % 51,4 (27,4–75,3) 51 (26,6–76) 53,5 (32,9–72,4) 51,5 (27,6–75,2)
IS lymphocytes, % 1,4 (0,5–2,7) 1,2 (0,4–2,8) 1,6 (0,5–2,6) 1,6 (0,7–2,6)
IS macrophages, % 23,8 (11,1–44,3) 23,8 (10,6–45,6) 23 (12,2–39,9) 26,4 (13–45)
FeNO, ppb 24 (14–49) ** 25 (14–52) 20 (12–42) † 22 (12–35)
*Global p-value; † compares BMI 30–35 to BMI < 30 group; ∞ compares BMI ≥ 35 to BMI < 30 groups; x compares BMI ≥ 35 to BMI 30–35 groups. */†/ ∞/ x :
p < 0,05. **/††/ ∞∞/x x:p < 0,01. ***/†††/∞∞∞/ x x x: p < 0,001. ****/††††/∞∞∞∞/ x x x x: P < 0,0001.
CRP: C reactive protein. IgE: immunoglobulin E. IS: induced sputum. FeNO: fractional exhaled nitric oxide. Ppb: part per billion.
Fig. 1. Proportions of airway inflammatory phenotypes in asthmatics classified
according to BMI.
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Uncontrolled obese asthmatics showing a good response to increase
in ICS dose had poorer baseline ACQ (3.27 ± 1.22 vs 2.24 ± 1.11,
p < 0.01), lower CRP levels (2.9 (0.9–5.2) vs 5 (3.2–8.8), p = 0.04),
higher sputum eosinophil counts either taken in percentage (23.6%
(3.1–50) vs 6.2% (0.6–15), p = 0.01) or in absolute value (393
(35–1170) vs 72 (2–274), p = 0,02) and higher FENO levels (48
(20–74) vs 18 (12–43), p = 0.01). Uncontrolled obese asthmatics who
worsened their asthma after increasing the dose of ICS had lower FVC
(78%±19% vs 91%±17%, p = 0.04), lower sputum eosinophil
counts (1.4% (0.6 – 9.8) vs 11% (1.8–29), p = 0.03) and higher sputum
neutrophil counts (73.4% (58–90) vs 43.4% (16–71), p = 0.04). After
exclusion of current smokers, we found exactly the same characteristics
of good and poor response to ICS. We did not find any differences in
treatment response when looking at the age of onset.
4. Discussion
Obese asthmatics represent 20% of our asthmatic population.
Obesity is associated with poor asthma control and quality of life and
obese asthmatics exhibit signs of systemic inflammation.
We found that obese asthmatics have the same predictors of re-
sponse to ICS than non-obese. The ‘‘obesity-associated asthma’’ phe-
notype includes a subgroup of patients with eosinophilic inflammation
who will show a good response to ICS and another subgroup who is
characterized by low FVC and neutrophilic inflammation who may even
deteriorate with the increase in ICS dose.
In a general population of asthmatics, our data report that 20% are
obese. Ford et al [21] found that 27.3% out of 13,953 asthmatics had a
BMI>30. Female was the predominant gender in our study. As pre-
vious studies, we found the same proportion of atopic patients and si-
milar FEV1 and FEV1/FVC in obese versus normal weight asthmatics
[22,23]. Obese asthmatics had poorer asthma control and quality of life
than those with normal weight. Only a low proportion of obese asth-
matics reach asthma control with classic asthma therapy in our study
which is in line with previous reports [10,11]. Our obese asthmatic
population received higher doses of ICS, SABA and more frequently
anti-leukotrienes and LABA than their non-obese counterpart. FVC was
decreased in obese as compared to lean patients. This finding was al-
ready found by Holguin et al [23]. Alteration of thoracic mechanics
may indeed contribute to greater symptom burden and poorer asthma
control. As a consequence, respiratory physicians are tented to increase
the dose of ICS according to GINA guidelines. However, thoracic and
pulmonary compliance in those patients may be reduced due to thoracic
compression by abdominal obesity. Obesity indeed reduces the down-
ward movement of the diaphragm and change chest wall properties.
These changes in the balance of forces that normally act on the lung
increase the stiffness of the respiratory system [24] and reduce oper-
ating lung volumes, contributing to dyspnea [25]. A step-up in ICS dose
in the absence of type 2 inflammation won’t improve [26–28] and may
even worsen asthma control due to side-effects.
In obese asthmatics, poor diet quality, physical inactivity and con-
sequent excess of adipose tissue independently activates inflammatory
pathways [29]. We found higher levels of blood leucocytes, CRP and
fibrinogen and increased numbers of sputum neutrophils in our obese
Table 3
Univariate and multivariate linear regression models to assess the relationship between Asthma control questionnaire (ACQ) and a set of covariates.
ACQ UNIVARIATE MULTIVARIABLE With stepwise selection
Univariate Estimate (SE) P-value Estimate (SE) P-value
Tobacco Current Ex-smokers 0.57 (0.090)
0.16 (0.083)
< 0.0001 0.56 (0.085) < 0.0001
BMI 0.036 (0.0071) < 0.0001 0.027 (0.0071) 0.0002
FEV1 −0.033 (0.0014) < 0.0001 −0.029 < 0.0001
FVC −0.033 (0.0019) < 0.0001











Ln Leucocytes 1.10 (0.12) < 0.0001
Ln Lympho % −0.69 (0.11) < 0.0001
Ln Blood Eosinophils (/µL) 0.18 (0.041) < 0.0001
Ln Blood Neutrophils (/µL) 0.73 (0.085) < 0.0001
Ln Basophils (/µL) 0.28 (0.059) < 0.0001
Ln Fibrinogen 0.35 (0.18) 0.046
Ln CRP 0.17 (0.034) < 0.0001
Ln Sputum Macrophages −0.23 (0.035) < 0.0001
Ln Sputum Eosinophils 0.13 (0.023) < 0.0001
Ln Sputum Lympho, AV 0.087 (0.025) 0.0004
Ln Sputum Neutrophils, AV 0.090 (0.02) < 0.0001
Ln Sputum Eosinophils, AV 0.12 (0.018) < 0.0001 0.095 < 0.0001
Independent variables included were age, forced expiratory volume in one second (FEV1), Forced vital capacity (FVC), FEV1/FVC, Asthma control test (ACT), Asthma
quality of life questionnaire (AQLQ), Body mass index (BMI), tobacco smoking (non-smokers – ex-smokers – current smokers) and pack-years, and were log-
transformed for FeNO, blood leucocytes, fibrinogen, CRP, IgE and induced sputum cell counts. Inhaled corticosteroids (ICS) was divided in three groups according to
tertiles (< 400,≥400-1000,≥1000). Significant variables in the univariate model are reported in the table. A multivariate analysis with stepwise selection was done
including all significant variables from the univariate model.
Table 4
Proportion of good and poor responders to an ICS step-up therapy in uncontrolled asthma classified according to BMI.
ACQ ≥ 1,5, BMI < 30 ACQ ≥ 1,5, BMI ≥ 30 P value
ICS step-up received (Y,%) 146 (26%) 57 (32%) > 0,05
Good responders 88 (60%) 29 (53%) > 0,05
Poor responders 33 (23%) 17 (31%) > 0,05
ACQ: asthma control questionnaire. BMI: body mass index. ICS: inhaled corticosteroids.
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asthmatic population. It was previously found that obesity is associated
with systemic inflammation such as blood neutrophilia, elevated CRP
and leptin levels [30]. Obesity is regarded as a low-grade chronic pro-
inflammatory state that affects the cellular and molecular signaling
pathways of the immune system. The total leukocyte count correlates
with the degree of obesity and CRP and fibrinogen have been found to
be elevated in obese asthmatics in a previous report [31]. We found
higher sputum neutrophil counts in the obese subpopulation. It has
been suggested that late-onset obese women have an increase in sputum
neutrophils [32] and that fatty acids should activate the immune system
by activation of toll-like receptors on epithelial cells conducing in nu-
clear translocation of NFκβ and to the production of pro-inflammatory
cytokines (TNFα, IL-6 and IL-1) inducing neutrophilic inflammation
[33]. We also know that exhaled air 8-isoprostane level, reflecting
oxidative stress, is increased in obese asthmatics [8,34]. Scott et al. [33]
have also shown that sputum neutrophils were associated with total
plasma saturated fatty acids and negatively with mono-unsaturated
fatty acids in men. Periyalil et al also found higher percentages of
sputum neutrophils in obese versus lean asthmatics [35]. Other studies
did however not find any significant increase in sputum neutrophils
[36,37]. Baseline FENO values were similar to previously reported
[22,23,38]. As other studies [39], we found that FENO was not corre-
lated to BMI. In a previous study, we did not find any association be-
tween BMI and inflammatory phenotypes [40].
We looked at the predictors of a good or a poor response to ICS step-
up therapy in obese uncontrolled asthmatics. Obese asthmatics who did
not exhibit signs of eosinophilic inflammation but increased sputum
neutrophils and low FVC were not improved by increasing the dose of
ICS. The role of mechanical effects on the lungs in this subpopulation is
more important and this may increase symptoms directly. This high-
lights the need to accurately define the contribution of obesity, as co-
morbidity, to the expression of asthma symptoms in patients on an
individual basis. Cluster analyses and clinical observation have shown
that obese asthmatics are not a uniform group. Several cluster analyses
have identified two major groups of obese asthmatics that are cate-
gorized by age of onset of asthma [16] as well as TH2 inflammation
[14].
Our results suggest that phenotyping obese asthma in different in-
flammatory phenotypes seems as important as in non-obese asthmatics
to predict the response to therapy. Previous studies have shown that
weight loss resulted in a dramatic improvement in asthma control by
improving lung mechanics [41] and systemic inflammation [38] but did
not show any effect on bronchial inflammation on biopsy [38] or
airway cellular inflammation [42]. Macgregor et al showed that weight
loss in obese asthmatics was associated with a 48%–100% remission of
asthma symptoms and use of asthma medication [43,44]. Dixon et al
found two groups of obese asthmatics, one with early onset disease and
high IgE that did not improve with surgery, and a second group with
low IgE that improved with surgery [14]. Furthermore, it has been
previously shown that inhaled corticosteroids treatment causes similar
improvements in FEV1 in obese than non-obese asthmatics, despite
having considerably less effect on symptoms in the obese [10]. Nowa-
days, the current general GINA guidelines are used in obese patients but
we should be aware that asthma control questionnaires may not reflect
the reality of asthma control but may be influenced by obesity-related
symptoms. Weight loss does not improve airway eosinophilic in-
flammation. It is therefore probable that weight loss induced im-
provements in asthma control defined as symptoms, lung function and
use of medication due to a reduction in mass load on the respiratory
symptoms rather than improvements in asthma per se. In adults it ap-
pears that weight loss of at least 10% is required to produce a sig-
nificant improvement in asthma control [45]. De-conditioning from
lack of exercise could also play a role in the relationship between
obesity and the clinical expression of asthma [46]. It has been pre-
viously shown that exercise can reduce allergic airway inflammation
through effects on regulatory T-cell function in a murine asthma model
[47]. The approach of obese asthmatics should combine pharmacologic
and non-pharmacologic therapies, including exercise, weight loss and
dietary interventions and the stepping up ICS therapy should be re-
served to eosinophilic phenotype. Moreover future studies must in-
vestigate how diet changes and microbiome can affect outcomes in
obese asthmatics [48].
Weight reduction is likely to be at least as important as pharma-
cological therapy in obese adults with asthma symptoms. Whether
macrolides, targeting neutrophilic inflammation could be a therapeutic
option in obese asthmatics has not yet been investigated.
It has been argued that late onset non allergic obese asthma (LONA)
and early onset allergic obese asthma (EOA) were characterized by
different pathophysiology and response to treatment. EOA is more a
type-2 disease while LONA is driven by a non type-2 inflammation. We
did not find age of onset as a predictor of response to ICS treatment.
Most of the published studies on obese asthmatics have however
relied on self-reporting of physician diagnosis of asthma and recall
questionnaires for respiratory symptoms and medications which lead to
a clear risk of misdiagnosis. In this study, asthmatics were diagnosed
based on proof of airway variability or airway responsiveness to me-
thacholine challenge. We did not exclude current smokers in our real-
life study. Smoking may induce non type-2 inflammation and worsen
asthma symptoms. Cigarette exposure is responsible for neutrophilic
inflammation and neutrophils apoptosis leading to damage-associated
molecular pattern (DAMPs), which may amplify smoking induced
airway inflammation by promoting epithelial pro-inflammatory re-
sponse [49]. The proportion of smokers was however similar in obese
and normal-weight patients so we can suspect that smoking itself does
not explain the difference seen between obese and normal weight pa-
tients in terms of asthma control. Moreover a sub analysis after exclu-
sion of current smokers confirmed the same predictors of response to
inhaled corticosteroids. Smoking cessation however remain of upmost
importance in the management of asthmatics.
Our results suggest that respiratory physicians should measure in-
flammation, especially in these obese patients, to avoid unnecessary
step-up in ICS dose related to persistent symptoms of dyspnea. In the
presence of a “type-2” pattern, ICS will improve asthma symptoms
while in the presence of neutrophilic inflammation or a restriction
profile, weight loss may improve asthma outcomes and treatment
should involve bronchodilators and low to moderate doses of ICS.
Obesity is a well-known comorbidity in asthma and should be targeted
in addition to the treatment of cortico-sensitive inflammation. Future
research should aim to find novel biomarkers that might help identify
these sub-phenotypes [50].
In our unselected population of asthmatic, we found that markers of
bronchial eosinophilic inflammation such as FeNO [51,52] and sputum
eosinophils predict a good response to ICS in obese asthmatics while a
restrictive pattern and neutrophilic inflammation may identify a sub-
group of patients that can deteriorate with the increase in ICS dose. In
those patients, management of obesity should be the first choice. In-
creasing corticosteroid doses based on poor asthma control, as currently
recommended in current guidelines, may thus lead to ICS overtreatment
in non-eosinophilic obese asthma. Much attention should be paid to
eosinophilic markers in this particular population of asthmatics.
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